Skip to content
OpenCapital
Get started

Foghorn Therapeutics FHTX Q4 2024 Annual earnings

Reported March 6, 2025 · Before market open

Revenue$2.9MMiss by $5.8M
EPS-$0.30Beat by $0.13
Revenue estimate$8.7M
EPS estimate-$0.43

Next report

Aug 4, 2026 (In 6 days)
Revenue estimate$7.0M
EPS estimate-$0.23

Versus estimates

Revenue

Q1 2026$3.3MMiss by $4.7MQ4 2025$9.2MMiss by $904.7KQ3 2025$8.2MMiss by $1.3MQ2 2025$7.6MMiss by $616.0KQ1 2025$6.0MMiss by $287.7K
Q4 2024$2.9MMiss by $5.8M

Diluted EPS

Q1 2026-$0.29Miss by $0.01Q4 2025-$0.34Miss by $0.06Q3 2025-$0.25Beat by $0.06Q2 2025-$0.28Beat by $0.03Q1 2025-$0.30In line
Q4 2024-$0.30Beat by $0.13

Ask the moment Foghorn Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Foghorn Therapeutics report Q4 2024 earnings?
Foghorn Therapeutics (FHTX) reported Q4 2024 earnings on March 6, 2025 before market open.
What were Foghorn Therapeutics's Q4 2024 revenue and EPS?
Foghorn Therapeutics reported revenue of $2.9M and eps of $-0.30 for Q4 2024.
Did Foghorn Therapeutics beat estimates in Q4 2024?
Revenue missed the consensus estimate of $8.7M by $5.8M. EPS beat the consensus estimate of $-0.43 by $0.13.
Where can I find Foghorn Therapeutics's Q4 2024 SEC filings?
You can read the 10-K periodic report (0001628280-25-010933) directly on SEC EDGAR. The filing index links above go to sec.gov.